

# Neuroendocrine Tumors - Pipeline Review, H1 2020

<https://marketpublishers.com/r/NCBAD161478EN.html>

Date: June 2020

Pages: 795

Price: US\$ 2,000.00 (Single User License)

ID: NCBAD161478EN

## Abstracts

Neuroendocrine Tumors - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2020, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and

Unknown stages are 1, 3, 34, 29, 1, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).

The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Neuroendocrine Tumors - Overview

Neuroendocrine Tumors - Therapeutics Development

Neuroendocrine Tumors - Therapeutics Assessment

Neuroendocrine Tumors - Companies Involved in Therapeutics Development

Neuroendocrine Tumors - Drug Profiles

Neuroendocrine Tumors - Dormant Projects

Neuroendocrine Tumors - Discontinued Products

Neuroendocrine Tumors - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Neuroendocrine Tumors, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Neuroendocrine Tumors - Pipeline by Aadi Bioscience Inc, H1 2020  
Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H1 2020  
Neuroendocrine Tumors - Pipeline by Akeso Inc, H1 2020  
Neuroendocrine Tumors - Pipeline by AnHeart Therapeutics Inc, H1 2020  
Neuroendocrine Tumors - Pipeline by Aquestive Therapeutics Inc, H1 2020  
Neuroendocrine Tumors - Pipeline by Ascil Proyectos SL, H1 2020  
Neuroendocrine Tumors - Pipeline by AstraZeneca Plc, H1 2020  
Neuroendocrine Tumors - Pipeline by Beijing Foreland Pharma Co Ltd, H1 2020  
Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim International GmbH, H1 2020  
Neuroendocrine Tumors - Pipeline by BriaCell Therapeutics Corp, H1 2020  
Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Co, H1 2020  
Neuroendocrine Tumors - Dormant Projects, H1 2020  
Neuroendocrine Tumors - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Neuroendocrine Tumors, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Aadi Bioscience Inc  
Advanced Accelerator Applications SA  
Akeso Inc  
AnHeart Therapeutics Inc  
Aquestive Therapeutics Inc  
Ascil Projectos SL  
AstraZeneca Plc  
Beijing Foreland Pharma Co Ltd  
Boehringer Ingelheim International GmbH  
BriaCell Therapeutics Corp  
Bristol-Myers Squibb Co  
Camurus AB  
CanBas Co Ltd  
Clarity Pharmaceuticals Pty Ltd  
Crinetics Pharmaceuticals Inc  
Dauntless Pharmaceuticals Inc  
DexTech Medical AB  
Eli Lilly and Co  
Enterome Bioscience SA  
EpicentRx Inc  
Esanex Inc

Esperance Pharmaceuticals Inc  
Exelixis Inc  
GEMoAB Monoclonals GmbH  
HEC Pharm Co Ltd  
Highlight Therapeutics SL  
Hutchison MediPharma Ltd  
Innovent Biologics Inc  
INVENT Pharmaceuticals Inc  
Ipsen SA  
Jubilant DraxImage Inc  
Karyopharm Therapeutics Inc  
Lexicon Pharmaceuticals Inc  
Lixte Biotechnology Holdings Inc  
Mateon Therapeutics Inc  
Merck & Co Inc  
Merck KGaA  
Millennium Pharmaceuticals Inc  
MimiVax LLC  
Mina Therapeutics Ltd  
Molecular Targeting Technologies Inc  
Molecular Templates Inc  
Novovent Pharmaceuticals Inc  
Northwest Biotherapeutics Inc  
Novartis AG  
Oncoceutics Inc  
Oncology Venture U.S. Inc  
Ono Pharmaceutical Co Ltd  
Orano Med LLC  
Pfizer Inc  
Pharma Mar SA  
Pharmathen Global BV  
Progenics Pharmaceuticals Inc  
Provectus Biopharmaceuticals Inc  
Regulaxis SAS  
Rhizen Pharmaceuticals SA  
Seneca Therapeutics Inc  
Shanghai Junshi Bioscience Co Ltd  
Sichuan Huiyang Life Science and Technology Corp  
Strongbridge Biopharma plc

Suntec Medical (Taiwan) Inc  
Taiho Oncology Inc  
Tarveda Therapeutics Inc  
Teclison Ltd  
Trio Medicines Ltd  
Vanquish Oncology Inc  
Veana Therapeutics LLC  
Vyriad Inc  
Xencor Inc



## I would like to order

Product name: Neuroendocrine Tumors - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/NCBAD161478EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NCBAD161478EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970